Walid Abi‐Saab

4.3k total citations
42 papers, 3.3k citations indexed

About

Walid Abi‐Saab is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Walid Abi‐Saab has authored 42 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 14 papers in Cellular and Molecular Neuroscience and 12 papers in Pharmacology. Recurrent topics in Walid Abi‐Saab's work include Neuroscience and Neuropharmacology Research (10 papers), Treatment of Major Depression (8 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Walid Abi‐Saab is often cited by papers focused on Neuroscience and Neuropharmacology Research (10 papers), Treatment of Major Depression (8 papers) and Neurotransmitter Receptor Influence on Behavior (7 papers). Walid Abi‐Saab collaborates with scholars based in United States, United Kingdom and Switzerland. Walid Abi‐Saab's co-authors include John H. Krystal, Ralitza Gueorguieva, Steven Madonick, Thomas B. Cooper, Ayşenil Belger, Deepak Cyril D’Souza, Mario Saltarelli, Deepak Cyril D’Souza, Gabriel Braley and Kimberlee Forselius-Bielen and has published in prestigious journals such as The Lancet, Blood and Annals of Neurology.

In The Last Decade

Walid Abi‐Saab

41 papers receiving 3.2k citations

Peers

Countries citing papers authored by Walid Abi‐Saab

Since Specialization

Citations

This map shows the geographic impact of Walid Abi‐Saab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Walid Abi‐Saab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Walid Abi‐Saab more than expected).

Fields of papers citing papers by Walid Abi‐Saab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Walid Abi‐Saab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Walid Abi‐Saab. The network helps show where Walid Abi‐Saab may publish in the future.

Co-authorship network of co-authors of Walid Abi‐Saab

This figure shows the co-authorship network connecting the top 25 collaborators of Walid Abi‐Saab. A scholar is included among the top collaborators of Walid Abi‐Saab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Walid Abi‐Saab. Walid Abi‐Saab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial 2018 ·The Lancet ·Désirée van der Heijde, Xenofon Baraliakos, Lianne S. Gensler, Walter P. Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi‐Saab, Chantal Tasset, Luc Meuleners, R. Besuyen, Thijs Hendrikx, Neelufar Mozaffarian, Ke Liu, Joy M. Greer, Atul Deodhar, Robert Landewé	194
2	Liver MRI is more precise than liver biopsy for assessing total body iron balance: a comparison of MRI relaxometry with simulated liver biopsy results 2015 ·Magnetic Resonance Imaging ·John C. Wood, (unknown), Hugh Young Rienhoff, Walid Abi‐Saab, Ellis J. Neufeld	48
3	A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of α4β2 Agonist ABT-894 in Adults with ADHD 2012 ·Neuropsychopharmacology ·Earle Bain, Weining Robieson, Yili Pritchett, Τushar Garimella, Walid Abi‐Saab, George Apostol, James J. McGough, Mario Saltarelli	46
4	The scopolamine model as a pharmacodynamic marker in early drug development 2011 ·Psychopharmacology ·Robert Lenz, Jeffrey D. Baker, Charles Locke, Lynne E. Rueter, Eric G. Mohler, Keith Wesnes, Walid Abi‐Saab, Mario Saltarelli	47
5	AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials 2011 ·Movement Disorders ·Daniela Berg, Jana Godau, Claudia Trenkwalder, Karla Eggert, (unknown), Alexander Storch, Heiko Huber, (unknown), María Stamelou, Vincent Ries, Martin Wolz, Christine Schneider, Thérèse Di Paolo, F. Gasparini, Sam Hariry, Marc Vandemeulebroecke, Walid Abi‐Saab, (unknown), Donald R. Johns, Baltazar Gomez‐Mancilla	145
6	Safety and Efficacy of ABT-089 in Pediatric Attention-Deficit/Hyperactivity Disorder: Results from Two Randomized Placebo-Controlled Clinical Trials 2010 ·Journal of the American Academy of Child & Adolescent Psychiatry ·Timothy E. Wilens, Laura M. Gault, Ann Childress, Christopher J. Kratochvil, (unknown), Coleen Hall, (unknown), Weining Robieson, Τushar Garimella, Walid Abi‐Saab, George Apostol, Mario Saltarelli	32
7	Long-Term Safety of Divalproex Sodium Extended-Release in Children and Adolescents with Bipolar I Disorder 2009 ·Journal of Child and Adolescent Psychopharmacology ·Laura Redden, Melissa P. DelBello, Karen Dineen Wagner, Timothy E. Wilens, Shishuka Malhotra, Patricia Wozniak, (unknown), Nicholas J. Greco, (unknown), Walid Abi‐Saab, Mario Saltarelli	27
8	Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925 2009 ·The International Journal of Neuropsychopharmacology ·Ariel Graff‐Guerrero, Laura Redden, Walid Abi‐Saab, David A. Katz, Sylvain Houle, (unknown), Anahita Bhathena, (unknown), Mario Saltarelli, Shitij Kapur	57
9	Divalproex Extended‐Release in Adolescent Migraine Prophylaxis: Results of a Randomized, Double‐Blind, Placebo‐Controlled Study 2008 ·Headache The Journal of Head and Face Pain ·George Apostol, Roger Cady, Genevieve Laforet, Weining Robieson, (unknown), Walid Abi‐Saab, Mario Saltarelli	43
10	Divalproex ER Combined with Olanzapine or Risperidone for Treatment of Acute Exacerbations of Schizophrenia 2008 ·Neuropsychopharmacology ·Daniel E. Casey, David G. Daniel, Carol A. Tamminga, John M. Kane, Tram Tran-Johnson, Patricia Wozniak, Walid Abi‐Saab, Jeff Baker, Laura Redden, Nicholas J. Greco, Mario Saltarelli	41
11	Decreased hippocampal volume on MRI is associated with increased extracellular glutamate in epilepsy patients 2008 ·Epilepsia ·Idil Çavuş, Jullie W. Pan, Hoby P. Hetherington, Walid Abi‐Saab, Hitten P. Zaveri, Kenneth P. Vives, John H. Krystal, Susan S. Spencer, Dennis D. Spencer	75
12	Safety and Tolerability of Divalproex Sodium Extended‐Release in the Prophylaxis of Migraine Headaches: Results of an Open‐Label Extension Trial in Adolescents 2008 ·Headache The Journal of Head and Face Pain ·George Apostol, Ann Pakalnis, Genevieve Laforet, Weining Robieson, (unknown), Walid Abi‐Saab, Mario Saltarelli	17
13	A Randomized, Placebo-Controlled, Multicenter Study of Divalproex Sodium Extended Release in the Treatment of Acute Mania 2006 ·The Journal of Clinical Psychiatry ·Charles L. Bowden, Alan C. Swann, Joseph R. Calabrese, (unknown), Patricia J. Wozniak, Michelle A. Collins, Walid Abi‐Saab, Mario Saltarelli, (unknown)	87
14	Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction 2005 ·Biological Psychiatry ·Deepak Cyril D’Souza, Walid Abi‐Saab, Steven Madonick, Kimberlee Forselius-Bielen, (unknown), Gabriel Braley, Ralitza Gueorguieva, Thomas B. Cooper, John H. Krystal	452
15	Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine 2005 ·Psychopharmacology ·Hyun Sang Cho, Deepak Cyril D’Souza, Ralitza Gueorguieva, Edward Perry, Steven Madonick, Laurence P. Karper, Anissa Abi‐Dargham, Ayşenil Belger, Walid Abi‐Saab, Deborah S. Lipschitz, (unknown), John Seibyl, John H. Krystal	33
16	Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine 2005 ·Archives of General Psychiatry ·John H. Krystal, Edward Perry, Ralitza Gueorguieva, Ayşenil Belger, Steven Madonick, Anissa Abi‐Dargham, Thomas B. Cooper, Lisa Macdougall, Walid Abi‐Saab, Deepak Cyril D’Souza	258
17	Ritanserin antagonism of m-chlorophenylpiperazine effects in neuroleptic-free schizophrenics patients: support for serotonin-2 receptor modulation of schizophrenia symptoms 2002 ·Psychopharmacology ·Walid Abi‐Saab, John Seibyl, Cyril D’Souza, Laurence P. Karper, (unknown), Anissa Abi‐Dargham, Ma‐Li Wong, (unknown), (unknown), George R. Heninger, Dennis S. Charney, John H. Krystal	18
18	Transduction of Human GAD67 cDNA into Immortalized Striatal Cell Lines Using an Epstein–Barr Virus-Based Plasmid Vector Increases GABA Content 2000 ·Experimental Neurology ·Concepcion Conejero‐Goldberg, Carlo Tornatore, Walid Abi‐Saab, Maria Chiara Monaco, Ora Dillon‐Carter, (unknown), John D. Elsworth, William J. Freed	20
19	5-HT2 Receptor Regulation of Extracellular GABA Levels in the Prefrontal Cortex 1999 ·Neuropsychopharmacology ·Walid Abi‐Saab	141
20	The NMDA Antagonist Model for Schizophrenia: Promise and Pitfalls 1998 ·Pharmacopsychiatry ·Walid Abi‐Saab, Deepak Cyril D’Souza, Bita Moghaddam, John H. Krystal	163

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact